€
0. 20
-0
-1.4852%
€
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
0 Eps
€ 0.2
Previous Close Want to track AJW and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
AJW closed yesterday lower at €0.2, a decrease of -1.4852% from Wednesday's close, completing a monthly decrease of -4.3269% or -€0.01. Over the past 12 months, AJW stock lost -26.8382%.
AJW is not paying dividends to its shareholders.
The last earnings report, released on May 08, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Anges Inc. has completed 3 stock splits, with the recent split occurring on Jul 29, 2014.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on JPX (JPY).
AJW Chart
Anges Inc. (AJW) FAQ
What is the stock price today?
The current price is €0.20.
On which exchange is it traded?
Anges Inc. is listed on XDUS.
What is its stock symbol?
The ticker symbol is AJW.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Anges Inc. ever had a stock split?
Anges Inc. had 3 splits and the recent split was on Jul 29, 2014.
Anges Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ei Yamada CEO | XDUS Exchange | JP3127700007 ISIN |
| JP Country | 55 Employees | - Last Dividend | 26 Dec 2013 Last Split | - IPO Date |
Overview
AnGes, Inc. is a biopharmaceutical company founded in 1999, focusing on the research and development of gene-based medical therapies. Originally known as AnGes MG, Inc., the company underwent a name change to AnGes, Inc. in July 2017. With its headquarters in Ibaraki, Japan, AnGes is at the forefront of developing innovative solutions for a range of diseases by leveraging gene therapy and nucleic acid medicines. Its core research and collaborative efforts with prestigious institutions like Osaka University underscore its commitment to addressing unmet medical needs.
Products and Services
AnGes, Inc. offers a variety of products and services aimed at combating a range of diseases through cutting-edge gene therapy and nucleic acid technology. Below is a detailed look at their key developments:
- Hepatocyte Growth Factor (HGF) Plasmid: This is AnGes's lead product, a gene therapy focused on the treatment of ischemic diseases. It represents a groundbreaking approach in the field of regenerative medicine, aiming to improve blood flow and encourage tissue repair in affected areas.
- NF-kB Decoy Oligonucleotide: This nucleic acid medicine is designed to suppress inflammation, offering a novel treatment option for conditions associated with chronic inflammation, including low back pain. By targeting the NF-kB pathway, it prevents the transcription of genes involved in inflammation.
- Atopic Dermatitis and Asthma Treatments: The company is also exploring drugs targeting atopic dermatitis and asthma, reinforcing its commitment to providing solutions for inflammatory and allergic conditions.
- Medical Devices for Vascular Medicine: AnGes is developing medical devices aimed at the prevention and treatment of vascular diseases, indicating a multidisciplinary approach to treating circulatory system disorders.
- Cervical Intraepithelial Neoplasia (CIN) Therapeutic Vaccines for Cervical Cancer: Another significant area of research is the development of therapeutic vaccines aimed at treating CIN to prevent cervical cancer. This approach represents a potential shift towards more preventive strategies in oncology.
- DNA Vaccines for High Blood Pressure: In collaboration with Osaka University, AnGes is working on DNA vaccines targeting high blood pressure, a common but serious condition that can lead to cardiovascular diseases if untreated.
Contact Information
Address: Saito Bio-Incubator
Phone: +81 72 641 8011
Website: https://www.anges.co.jp
